Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
about
A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - A final reportClinical trials in pediatric neuro-oncology: what is missing and how we can improve.Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.Can metronomic maintenance with weekly vinblastine prevent early relapse/progression after bevacizumab-irinotecan in children with low-grade glioma?Optic Pathway Gliomas in Neurofibromatosis Type 1.Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology.
P2860
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@en
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@nl
type
label
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@en
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@nl
prefLabel
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@en
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@nl
P2093
P2860
P1476
Single agent vinorelbine in pediatric patients with progressive optic pathway glioma.
@en
P2093
Andrea Maria Cappellano
Antonio Sergio Petrilli
Frederico Adolfo Silva
Nasjla Saba da Silva
Priscila Mendes Paiva
Sergio Cavalheiro
P2860
P2888
P304
P356
10.1007/S11060-014-1652-6
P50
P577
2014-11-01T00:00:00Z